Stellar Biotechnologies, Inc. (OTCQB: SBOTF), a leading
provider of keyhole limpet hemocyanin (KLH) protein, yesterday announced a
collaboration agreement with Ostiones Guerrero SA de CV that will allow Stellar
to greatly expand its KLH production capacity in the future. Through this
agreement, the two businesses will utilize their considerable expertise in
marine-based industries in order to design and develop an
environmentally-sustainable KLH production facility in Baja California, Mexico.
Through the construction of this facility, Stellar will gain exclusive access
to an additional site for hatchery and maturation of keyhole limpets, as well
as production of KLH.
“This collaboration has far-reaching, positive implications
for Stellar,” Frank Oakes, president and chief executive officer of Stellar,
stated in a news release. “In addition to the clear operational security
offered by a second site, the partnership with Ostiones provides Stellar the
opportunity to extend our leadership in the sustainable manufacture of KLH
while ensuring protection of a valuable ocean resource and natural habitat.”
Environmental protection is particularly important to the
future financial success of Stellar, as the source of KLH protein, the giant
keyhole limpet, is native to a limited stretch of the Pacific Ocean coastline.
As a result, the company has developed a proprietary harvesting process that
does not harm the giant keyhole limpets, ensuring a sustainable production
process that can be scaled to meet the consistently rising demands of the
biotechnology industry as the clinical use of novel immunotherapies continues
to increase.
According to the terms of the agreement, Stellar will be
responsible for certain leasehold improvements and construction of structures
and utilities at Ostiones’s Baja California facility. Ostiones will provide
labor and operational support, as needed, and the two partners expect to enter
into a second deal regarding the use of site resources and utilities at a later
date.
Through this agreement, Stellar will be in a strong
strategic position to capitalize on the forecast market growth for KLH protein.
In its fiscal quarter ending March 2015, the company demonstrated the
biotechnology industry’s rising interest in its product by posting a 64 percent
year-over-year increase in revenue as a result of increased sales volume. For
prospective shareholders, Stellar’s foresight in meeting future market demand
highlights the quality of its leadership team, as well as the overall
marketability of its product. Look for the company to leverage this progress in
the coming months, providing a platform for sustainable investor returns moving
forward.
For more information, visit www.stellarbiotech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment